![Michael Murray](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Murray
Analyst-Equity bei BVF Partners LP
Aktive Positionen von Michael Murray
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BVF Partners LP
![]() BVF Partners LP Investment ManagersFinance BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts. | Analyst-Equity | 01.05.2013 | - |
Karriereverlauf von Michael Murray
Ehemalige bekannte Positionen von Michael Murray
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Leerink Partners LLC
![]() Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Analyst-Equity | 01.09.2010 | 01.05.2013 |
Palvella Therapeutics, Inc.
![]() Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Michael Murray
Harvard University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Analyst-Equity | 2 |
Undergraduate Degree | 1 |
Director/Board Member | 1 |
Sektoral
Finance | 3 |
Consumer Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
BVF Partners LP
![]() BVF Partners LP Investment ManagersFinance BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts. | Finance |
Leerink Partners LLC
![]() Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Finance |
Palvella Therapeutics, Inc.
![]() Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Health Technology |
- Börse
- Insiders
- Michael Murray
- Erfahrung